About Pramodini Medicare IPO
Pramodini Medicare IPO Details
Pramodini Medicare IPO is a 100% book-built issue of ₹69.04 crore, comprising a fresh issue of 0.54 crore worth up to ₹63.14 crore and an offer for sale (OFS) of 5.04 lakh shares worth up to ₹6 crore, with a face value of ₹10 per share. The company filed its DRHP with SEBI on April 23, 2026.
The price band of the issue is set between ₹110 to ₹118 crore and the lot size for an application is 1,200 shares. The minimum amount of investment required by an individual investor is ₹2,83,200 (2,400 shares). The IPO will open for subscription from August 12 to 14, 2026, on the NSE SME platform, with a tentative listing date fixed as August 19, 2026. The book-running lead manager of the issue is Smart Horizon Capital Advisors Private Limited, while the registrar to the offer is Purva Sharegistry (India) Private Limited.
Pramodini Medicare IPO Date & Timeline
The Pramodini Medicare IPO is officially set to open for subscription on Aug 12, 2026 and will close on Aug 14, 2026. The company initially filed its Draft Red Herring Prospectus (DRHP) on April 23, 2026 and has now finalized its schedule following SEBI approval. Once the subscription window closes, allotment is expected on Aug 17, 2026. Following this, the firm will initiate refunds and credit shares to successful investors' demat accounts on Aug 18, 2026. Finally, shares of Pramodini Medicare Ltd. are tentatively scheduled to list on the stock exchanges on Aug 19, 2026.
Pramodini Medicare IPO Timeline
| IPO Open Date | Wed, Aug 12, 2026 |
| IPO Close Date | Fri, Aug 14, 2026 |
| Basis of Allotment | Mon, Aug 17, 2026 |
| Initiation of Refunds | Tue, Aug 18, 2026 |
| Credit of Shares to Demat | Tue, Aug 18, 2026 |
| Listing Date | Wed, Aug 19, 2026 |
| Cut-off time for UPI mandate confirmation | - |
Pramodini Medicare IPO Details
| Detail | Description |
|---|---|
| IPO Date | 12 to 14 Aug, 2026 |
| Listing Date | 19 Aug, 2026 |
| Face Value | ₹ 10 Per Equity Share |
| Issue Price Band | ₹ 110 to ₹ 118 |
| Lot Size | 1,200 Shares |
| Sale Type | Fresh Issue + Offer For Sale |
| Total Issue Size | 58,51,200 shares (agg. up to ₹ 69 Cr) |
| Reserved for Market Maker | 3,36,000 shares (agg. up to ₹ 4 Cr) Shreni Shares Ltd. Rainbow Securities Pvt.Ltd. |
| Fresh Issue(Ex Market Maker) | 50,14,800 shares (agg. up to ₹ 59 Cr) |
| Offer for Sale | 5,00,400 shares of ₹10 (agg. up to ₹ 6 Cr) |
| Net Offered to Public | 55,15,200 shares (agg. up to ₹ 65 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 1,66,94,795 shares |
| Share Holding Post Issue | 2,20,45,595 shares |
Pramodini Medicare IPO GMP (Grey Market Premium)
“Grey Market Premium” or GMP is defined as the rate at which the IPO's shares are traded in the market before they are officially listed on the stock exchange.
The Pramodini Medicare IPO GMP is currently trading at ₹0, reflecting unofficial investors' sentiment ahead of the official listing. This premium suggests a potential listing price of ₹118, which is 0.00% above the issue price. While the Grey Market Premium is a key indicator of demand and investor appetite, it is important to remember that GMP is highly volatile and should not be the sole factor in your investment decisions.
IPO Estimated Listing Return
Based on the IPO Price of ₹118 (highest price band), the latest uploaded Grey Market Premium (GMP) of ₹0 and a lot size of 1200 shares.
Pramodini Medicare GMP TREND (DAILY UPDATES)
| GMP Date | IPO Price | GMP | Last Updated |
|---|---|---|---|
| 6 Aug 2026 | ₹118 | ₹0 | 6 Aug, 202602:50 PM |
| 05 Aug, 2026 | ₹118 | ₹0 | 05 Aug, 202610:56 AM |
Company Background
Pramodini Medicare Ltd. was incorporated as a private limited company on 12 September, 2000, in Hyderabad, Andhra Pradesh. The company provides technology-enabled diagnostic services, which include radiology and clinical laboratory and nuclear medicine services, to public & private hospitals, with a presence in 14 cities in India.
Also, Pramodini Medicare provides teleradiology services and healthcare services. Overall, they operate as a one-stop solution for all services to the patients through their operational network and also provide customised health and wellness packages to meet the patients' requirements. On November 12, 2025, the company converted into a public limited company to proceed with its public listing procedures.
Operations & Product Range
The core operating model of Pramodini Medicare Ltd. revolves around delivering technology-driven diagnostic solutions. The company's services are broadly categorised into 3 segments: Radiology (accounting for the vast majority of revenue), Clinical Laboratory and Nuclear Medicine.
The product range includes advanced imaging modalities such as MRI, CT scans, PET-CT, X-rays and comprehensive pathology testing. The target customers are diverse, operating via B2G, B2B and B2C channels. By embedding diagnostic centres within existing public and private hospital infrastructures, the company efficiently accesses captive patient bases.
Facilities & Capacity
The operational infrastructure of Pramodini Medicare Ltd. is strong, with 16 diagnostic centres established across 7 states, spanning 14 cities in India. The company also operates a centralised processing unit and laboratory in Vijayawada. The company plans to deploy new medical equipment to expand capacity at its existing Hubli centre in Karnataka, commence operations with new equipment at Manjeri in Kerala, establish a proposed centre in Bangalore and upgrade existing machinery in Vijayawada.
Brands & Market Presence
Pramodini Medicare Ltd. has established a recognisable market presence under its flagship brand, functioning primarily within the domestic Indian market. The company has a concentrated geographic footprint, with its most dominant presence in Andhra Pradesh (contributing 61.90% of its operational revenue in FY26).
It has also successfully scaled its presence in Karnataka, contributing 20.82%, alongside operations in Uttar Pradesh and West Bengal. By positioning its brand within established public and private healthcare institutions, the company leverages the credibility of its partners to reinforce its market position and ensure high visibility among target patient demographics.
Revenue Streams & Business Model
Pramodini Medicare Ltd. operates an asset-light diagnostic service business model centered on technology-enabled radiology, pathology, and nuclear medicine. The company generates revenue across 4 primary operational channels: Public-Private Partnerships (PPP) with government hospitals, Private-Private Partnerships with private hospitals, strategic collaborations with Public Sector Undertakings (PSUs), and standalone private diagnostic centers. This multi-channel framework enables the firm to deliver healthcare diagnostic solutions across tier-I, tier-II, and tier-III Indian cities.
Financial Performance
Pramodini Medicare Ltd. has shown a steady financial growth trajectory over the past 3 fiscal years. Total income increased from ₹35.79 crore in FY24 to ₹63.37 crore in FY26. The EBITDA also saw a consistent rise, moving from ₹15.53 crore in FY24 to ₹30.90 crore in FY26, with an EBITDA margin of 49.61% in FY26. The company’s most profitable financial stream remains its B2G Radiology segment, which drives the bulk of its top-line and bottom-line growth.
Management & Shareholding
The promoters of Pramodini Medicare Ltd. are Dr. Chalasani Kuldeep Kumar, Dr. Chalasani Kavitha, Ms. Chalasani Durga Aashritha, Ms. Chalasani Lalithakumari and M/s Sri Ram Medicare Private Limited. Before the IPO, the promoters held 85.71% stake in the company, but after the IPO, the promoters’ shareholding will be diluted as the offering includes 5 lakh shares to be sold by existing shareholders.
Board & Key Management
The leadership of Pramodini Medicare Ltd. is led by a team of experts with many years of experience. Dr. Chalasani Kuldeep Kumar serves as the Chairman & Managing Director and gives strategic direction to the firm, as well as manages the daily operations, along with Whole-Time Directors. To ensure good governance, the board includes Independent Directors Mr. A Ajay Kumar, Dr. Eshwar Chandra Nandury and Mr. Manas Dash for honest oversight. Together, this team uses its knowledge to help the company grow and stay successful.
Pramodini Medicare IPO Financial Information
Latest Revenue
62.29
₹ Crore
Profit After Tax
17.38
₹ Crore
Net Worth
53.15
₹ Crore
Total Borrowing
17.85
₹ Crore
| Period Ended | Assets | Revenue From Operations | Profit After Tax | Net Worth | Reserves & Surplus | Total Borrowing | |||
|---|---|---|---|---|---|---|---|---|---|
| 31 Mar 2026 | 93.62 | 62.29 | 17.38 | 53.15 | 36.46 | 17.85 | |||
| 31 Mar 2025 | 56.45 | 38.24 | 11.14 | 35.77 | 34.49 | 10.81 | |||
| 31 Mar 2024 | 48.78 | 35.23 | 7.14 | 24.75 | 23.46 | 11.96 | |||
| Amount in ₹ Crore | |||||||||
Pramodini Medicare Key Performance Indicator
| KPI | Values(31 Mar 2026) |
|---|---|
| ROE | 39.08 % |
| ROCE | 34.66 % |
| Debt/Equity | 0.34 |
| RoNW | 32.69 % |
| PAT Margin | 27.90 % |
| EBITDA Margin | 49.61 % |
| Price to Book Value | 3.71 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 10.41 | 7.88 |
| P/E (x) | 11.34 | 14.97 |
Pramodini Medicare IPO Objectives
The company aims to fund its Pramodini Medicare IPO proceeds for its strategic purposes:
- • Purchasing medical equipment for existing diagnostic centres
- • General corporate purposes
Pramodini Medicare IPO Review
Pramodini Medicare Ltd. operates in a highly specialized segment of the healthcare industry, positioning itself as a key partner for government and private hospitals through its asset-light partnership models. By embedding its diagnostic infrastructure within existing hospitals, the company benefits from a steady, captive patient base, which significantly reduces customer acquisition costs and bolsters its operational efficiency.
Financially, the company has exhibited strong top-line expansion, particularly evident in its revenue jump to ₹62.29 crore in FY26. The high EBITDA margins, hovering around 51%, highlight the lucrative nature of its core radiology services once initial capital expenditures are deployed. However, the business is highly capital-intensive, requiring frequent technological upgrades to remain relevant in a competitive market.
However, the company shows heavy reliance on Public-Private Partnerships (PPPs) and a limited number of institutional clients, which causes risk for its potential investors. In FY26, over 61% of revenue was derived from B2G channels. Any failure to renew these MOUs, or delays in government payments, could pose significant liquidity challenges. Furthermore, geographic concentration in Andhra Pradesh exposes the company to regional economic and political variables. Overall, the IPO presents a company with a proven execution model in the diagnostic sector, backed by strong margins and institutional partnerships. Investors must be aware of the financials and risk factors of the company, as the long-term trajectory will heavily depend on its ability to execute while mitigating risks associated with government contract dependency.
Conclusion
Pramodini Medicare IPO is an opportunity for investors to invest in a growing company that is an institutional participant's exposure to an established player in the Indian diagnostic space. The company's core business strengths lie in its strategic hospital partnerships, specialised focus on high-margin radiology services and an experienced management team. With this listing, the company aims to purchase medical equipments for its existing centres and to meet the day-to-day operational requirements.
Frequently Asked Questions
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
Asset-light, partnership-driven business model ensuring a captive patient base and lower marketing costs.
Specialised focus on high-margin radiology and advanced imaging services.
Strong geographic foothold and established relationships with public health agencies in Andhra Pradesh.
Demonstrated financial track record with consistent revenue growth and robust EBITDA margins.
Download regulatory filings
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 2400 | 283200 |
| Individual investors (Retail) (Max) | 2 | 2400 | 283200 |
| S-HNI (Min) | 3 | 3600 | 424800 |
| S-HNI (Max) | 7 | 8400 | 991200 |
| B-HNI (Min) | 8 | 9600 | 1132800 |